publication . Article . 2014

Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.

Jean-Yves Reginster; J. Badurski; Nicholas Bellamy; William G. Bensen; Roland Chapurlat; Xavier Chevalier; C. Christiansen; Harry K. Genant; F Navarro; P. N. Sambrook; ...
Open Access English
  • Published: 15 Jan 2014 Journal: Annals of the Rheumatic Diseases, volume 72, issue 2, page 179-86
  • Publisher: BMJ Group (GB)
  • Country: Belgium
Objective. Background Strontium ranelate is currently used for osteoporosis. The international, double-blind, randomised, placebo-controlled Strontium ranelate Efficacy in Knee OsteoarthrItis triAl evaluated its effect on radiological progression of knee osteoarthritis. Methods. Patients with knee osteoarthritis (Kellgren and Lawrence grade 2 or 3, and joint space width (JSW) 2.5-5 mm) were randomly allocated to strontium ranelate 1 g/day (n=558), 2 g/day (n=566) or placebo (n=559). The primary endpoint was radiographical change in JSW (medial tibiofemoral compartment) over 3 years versus placebo. Secondary endpoints included radiological progression, Western On...
Persistent Identifiers
Medical Subject Headings: musculoskeletal diseases
free text keywords: Osteoarthritis, Knee Osteoarthritis, Aged, Antirheumatic Agents/therapeutic use, Double-Blind Method, Female, Humans, Male, Middle Aged, Organometallic Compounds/therapeutic use, Osteoarthritis, Knee/drug therapy/radiography, Thiophenes/therapeutic use, Treatment Outcome, Human health sciences, General & internal medicine, Sciences de la santé humaine, Médecine générale & interne, Clinical endpoint, Osteoporosis, medicine.disease, medicine, Internal medicine, medicine.medical_specialty, WOMAC, Placebo, Population, education.field_of_study, education, Strontium ranelate, medicine.drug, Knee pain, medicine.symptom, business.industry, business, Surgery, Osteoarthritis
Related Organizations
Any information missing or wrong?Report an Issue